MEDIA CONTACT:
Myren Bobryk-Ozaki
(619)-555-7986
Myren.Bobryk-Ozaki@resmed.com

FOR IMMEDIATE RELEASE
Press Release

ResMed Unveils Brand New AI-Powered CPAP Machine

SAN DIEGO, December 8, 2023 – ResMed (NYSE: RMD, ASX: RMD) announced it is expanding its Continuous Positive Airway Pressure (CPAP) machine product portfolio to include an artificial intelligence-powered machine in the AirSense™ 12 series, the AirIntell™ Adapt. The innovative product will be available for purchase on December 11th.

The AirIntell™ Adapt expands on the capabilities of the AutoSet AirSense™ 10 and 11 series'. The new addition adjusts to the breathing patterns of patients by including all the advantages of artificial intelligence technology including high-level adaptation, fast and accurate decision-making, frequent and comprehensive reporting as well as ease of use and accessibility.

"We are always striving to match our product offerings with the latest technology to make sure our customers have access to the best of the best and, right now, that is artificial intelligence," said Lucile Blaise, President of Sleep and Respiratory Care at ResMed. "At ResMed, we believe every patient has individual needs so, the AirSense 12 Series, and the AirIntell™ Adapt, take all the greatest parts of our previous AirSense series' to make something more effective for those seeking a seamless sleep experience."

The AirIntell™ Adapt is available worldwide, in all 140+ countries ResMed services, through resmed.com/sleep-devices/airintell-adapt/.

The AI Revolution in Sleep

The evolution and ongoing development of artificial intelligence-focused technologies invigorated ResMed to start work on the AirIntell™ Adapt in 2021. When the new machine went into clinical trials, CPAP users preferred the capabilities of the AirIntell™ Adapt to previous AutoSense and VPAP models. Approximately 41.3% of users preferred it on day one, doubling its preference rating by the end of week two with an increase to nearly 85.9%.

Users reported the AirIntell™ Adapt to be quick in its adjustments to their sleeping patterns, easy compatibility to their existing tubes and masks as well as simple and convenient reports on their sleep, such as patterns of shallow breathing, through the myAir app.

"We are showing our commitment to improving the lives of our customers through advancements to the technology they rely on for a good night's sleep," added Blaise. "We really wanted to provide our customers with an option that would take the guesswork out of the picture because everyone should feel confident that, when their head hits the pillow, they will sleep well."

Over the years, the AirSense series' have been made with the needs of those who struggle with sleep in mind. Millions of people have a form of sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases that affect quality of life. The AirIntell™ Adapt joins ResMed's vast portfolio of CPAP systems to support these needs.

About ResMed

ResMed (NYSE: RMD, ASX: RMD) was founded in 1989 with the goal of pioneering innovative solutions to enable better care and improve quality of life while lowering overall costs of healthcare systems that keep people healthy. Operating in over 140 countries, ResMed provides transformational care with cloud-connected medical devices and software platforms for professionals, caregivers and people with chronic conditions that impact their sleeping patterns. By 2025, ResMed hopes to have helped change the lives of at least 250 million people.

To learn more about ResMed, visit resmed.com or follow @ResMed across social platforms such as Twitter (X) and LinkedIn.

# # #